Cardiovascular gene delivery: The good road is awaiting.
Atherosclerotic cardiovascular disease is a leading cause of death worldwide. Despite recent improvements in medical, operative, and endovascular treatments, the number of interventions performed annually continues to increase. Unfortunately, the durability of these interventions is limited acutely by thrombotic complications and later by myointimal hyperplasia followed by progression of atherosclerotic disease over time. Despite improving medical management of patients with atherosclerotic disease, these complications appear to be persisting. Cardiovascular gene therapy has the potential to make significant clinical inroads to limit these complications. This article will review the technical aspects of cardiovascular gene therapy; its application for promoting a functional endothelium, smooth muscle cell growth inhibition, therapeutic angiogenesis, tissue engineered vascular conduits, and discuss the current status of various applicable clinical trials.
Brewster
L P
LP
Department of Surgery, Loyola University Medical Center, Maywood, IL 60153, USA.
Brey
E M
EM
Greisler
H P
HP
D000818:Animals; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000235:genetics / Q000628:therapy*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods* / Q000639:trends; D006801:Humans; D018919:Neovascularization, Physiologic / Q000235:genetics; D016896:Treatment Outcome